

Osteoporosis Treatment Order Form

Phone: (877) 246 9104 Fax: (800) 783-9146 www.Biotekrx.com

| PATIENT INFORMATION (Complete or fax existing chart) | PRESCRIBER INFORMATION |
|--|---|
| Patient Name: | Prescriber Name: |
| Address: | |
| City, State, Zip: | DEA:Phone: |
| Phone:Alt.Phone: | Address:Fax: |
| DOB:Gender: M F Last 4 SSN: | City, State, Zip: |
| WT: HT: Allergies: | Contact Person: Phone: |
| INSURANCE INFORMATION - INSTEAD - just send us a copy of the patient's prescription / insurance cards (front & back) | |
| Primary Insurance: | RX Card (PBM): |
| City, State, Zip: | BIN:PCN: |
| Plan #: | City, State, Zip: |
| Group #: | Group #: |
| Phone: | Phone: |
| DIAGNOSIS/CLINICAL INFORMATION | |
| 733.0 Osteoporosis | |
| Does the patient have a history of osteoporotic fracture? | □ Yes □ No |
| Has the patient failed or is unable to tolerate bisphosphonate therapy? ☐ Yes ☐ No | |
| If yes, please explain: | |
| Does the patient have >1 risk factor for fracture? ☐ Yes ☐ No | |
| If yes, please explain: | |
| Will the patient be adequately supplemented with Calcium and | I Vitamin D? ☐ Yes ☐ No |
| Infusion Orders | |
| DRUG DOSE/STRENGTI | TH DIRECTIONS |
| Prolia® 60mg | Inject 60mg subcutaneously every 6 months |
| Reclast® (Zoledronic Acid) 5mg | Infuse 5mg IV once a year |
| SIGNATURE | |
| | |
| | |
| Χ | DATE: |
| Prescribing Physician Signature | |

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.

Clinical Oversight Committee - APPROVED 11/2022